
10

15

25

WHAT IS CLAIMED IS:

1. A compound having the formula (I):



(I)

or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5-7 membered ring containing 1 or 2 nitrogen ring atoms or an aza bicyclo octane ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)/(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-;

20 A is -C₀₋₄alkyl-;

B is $aryl(CH_2)_{0,3}$ –O–C(O)–, heteroaryl(CH₂)_{1,3}–O–C(O)–, indanyl(CH₂)_{0,3}–O–C(O)–, aryl(CH₂)_{1,3}–C(O)–, aryl-cyclopropyl–C(O)–, heteroaryl-cyclopropyl–C(O)–, heteroaryl(CH₂)_{1,3}–C(O)–, aryl(CH₂)_{1,3}–, heteroaryl(CH₂)_{1,3}–, aryl(CH₂)_{1,3}–NH–C(O)–, aryl(CH₂)_{1,3}–NH–C(NCN)–, aryl(CH₂)_{1,3}–SO₂–, heteroaryl(CH₂)_{1,3}–SO₂–, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-

 $X \text{ is H, OH, F, C$_{1-4}$alkyl, C$_{1-4}$alkoxy, N$_{2}$, or X taken with an adjacent bond is =0.} \\$

6cycloalkyl, C1-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

2. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring

B is $aryl(CH_2)_{0.3}$ –O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1} -4alkyl, C_{3} -6cycloalkyl, C_{1} -4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

3. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

20

25

5

10

15

atom; and

4. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

30

35

5. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4alkyl}$, $C_{1-4alkoxy}$, $C_{2-4alkynyl}$, trifluoromethyl, hydroxy, hydroxy $C_{1-4alkyl}$, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $C_{1-4alkyl}$

30

4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

6. The compound according to Claim 2, or pharmaceutically 5 acceptable salts thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms:

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

 7. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

 $8. \ \, {\rm The\ compound\ according\ to\ Claim\ 2,\ or\ pharmaceutically} \\ 25 \quad {\rm acceptable\ salts\ thereof,\ wherein} \\$

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_{0-4} alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(C_{1-2} alkyl), NH₂C(C_{1-2} alkyl), NH₂C(C_{1-2} alkyl), and the substitute of the sub

 $9. \ \ \, \text{The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein}$

10

15

20

25

30

35

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_{0-4} alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(CH₃)3-C-, or NH₂C(O)-.

10. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4alkyl}$, $C_{1-4alkoxy}$, $C_{2-4alkynyl}$, trifluoromethyl, hydroxy, hydroxyC_{1-4alkyl}, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_{0-4alkyl})(C_{0-4alkyl}), nitro, (C_{1-2alkyl})(C_{1-2alkyl})NCH₂₋, (C_{1-2alkyl})HNCH₂₋, Si(CH₃)₃-C-, or NH₂C(O)-.

11. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_{0-4} alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

12. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

15

35

13. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

14. The compound according to Claim 2, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3-C—, or NH2C(O)—.

20 15. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl(CH₂)_{1:3}-SO₂-, wherein the aryl is optionally substituted by
25 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

 The compound according to Claim 15, or pharmaceutically acceptable salts thereof, wherein

30 HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4alkyl}$, $C_{1-4alkoxy}$, $C_{2-4alkynyl}$, trifluoromethyl, hydroxy, hydroxyC_{1-4alkyl}, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_{0-4alkyl}))(C_{0-4alkyl}),

10

15

20

25

nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

 The compound according to Claim 15, or pharmaceutically acceptable salts thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4alkyl}$, $C_{1-4alkxy}$, $C_{2-4alkyyl}$, trifluoromethyl, hydroxy, hydroxy $C_{1-4alkyl}$, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,— $N(C_{0-4alkyl})$, ohro, $(C_{1-2alkyl})$ ($C_{1-2alkyl})$ ($C_{1-2alkyl})$ HNCH₂-, $(C_{1-2alkyl})$ HNCH₂-, $(C_{1-2alkyl})$ or N_{1-2} ($C_{1-2alkyl}$) N_{1-2} N_{1-2} ($C_{1-2alkyl}$) N_{1-2} N_{1-2}

 $18. \ \, {\rm The\ compound\ according\ to\ Claim\ 15, or\ pharmaceutically\ acceptable\ salts\ thereof,\ wherein}$

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), mitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

 The compound according to Claim 15, or pharmaceutically acceptable salts thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

30

20. The compound according to Claim 15, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

10

15

20

25

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), mitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂₋, (C₁₋₂alkyl)HNCH₂₋, Si(CH₃)₃-C-, or NH₂C(O)-.

21. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom: and

B is aryl(CH₂) $_{0.3}$ –O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

 ${\it 22. \ The compound according to Claim \ 21, or pharmaceutically acceptable salts thereof, wherein}$

 $Het Ar \ is \ a \ 6 \ membered \ heteroaromatic \ ring \ containing \ 2 \ nitrogen \ ring \ atoms;$

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

23. The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

35

10

15

20

25

30

35

24. The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), mitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)3-C-, or NH₂C(O)-.

25. The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

 $HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_1-4alkyl, C_1-4alkoxy, C_2-4alkynyl,$ trifluoromethyl, hydroxy, hydroxyC_1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0-4alkyl)(C_0-4alkyl), nitro, (C_1-2alkyl)(C_{1-2alkyl})NCH_2-, (C_1-2alkyl)HNCH_2-, Si(CH_3)_3-C-, or $NH_2C(O)-.$ \\$

 The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and B is aryl(CH₂) $_{0.3}$ -O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substitutent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

27. The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

28. The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

10

25

35

atom: and

 The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring

15 HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or
20 NH2C(O)-.

 $30. \ \, \text{The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein}$

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)_{1.3}–SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

The compound according to Claim 1, or pharmaceutically
 acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is heteroaryl(CH₂)_{1.3}–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substitutent independently is C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

10

20

25

atom; and

32. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring

B is $aryl(CH_2)_{1,3}$ –C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-4} 4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

33. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

34. The compound according to Claim 33, or pharmaceutically acceptable salts thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -aalkyl, C_1 -aalkyn, C_2 -aalkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -aalkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0 -aalkyl)(C_0 -aalkyl), nitro, (C_1 -aalkyl)(C_1 -aalkyl)NCH2-, (C_1 -aalkyl)HNCH2-, or NH2C(O)-.

35. The compound according to Claim 33, or pharmaceutically acceptable salts thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

35

15

20

25

35

36. The compound according to Claim 33, or pharmaceutically acceptable salts thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2-, (C_1 -2alkyl)HNCH2-, Si(C_1 -3alkyl)- C_1 -0 or NH2C(C_1 -2alkyl)- C_1 -10 or NH2C(C_1 -2alkyl)- C_1 -2alkyl)- C_1 -2alkyl

37. The compound according to Claim 33, or pharmaceutically acceptable salts thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

38. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is heteroaryl(CH₂)_{1.3}–O–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4} alkyl, C_{3-6} 6cycloalkyl, C_{1-4} alkoxy, trifluoromethyl, bromo, fluoro, or chloro;

 $\mbox{39. The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein}$

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring

30 atom; and

 $\label{eq:Bisaryl} B \ is \ aryl(CH2)_{1.3}-NH-C(NCN)-, \ wherein the \ aryl \ is \ optionally substituted by 1-5 substitutents, each substitutent independently is $C_{1.4}$ alkyl, $C_{3.6}$ (Cycloalkyl, $C_{1.4}$ alkoxy, trifluoromethyl, bromo, fluoro, or chloro.$

NH NH	

	NHG NNN 1-RV
	COO NO N

FOR STANK		
SH CH	CH3	ON OH HIN, N
HN N	HN N	O N HN F ₃ C
O HN N	AN HAM	
HO-NH -	·	19V-164

	O LA POLITICA	Br NH NO
NS-NH-ON-S		
CI_N_NH_NH_NH_NH_NH_NH_NH_NH_NH_NH_NH_NH_N		
		NH2 N H
		F N. II
		CI_N_NH

or a pharmaceutically acceptable salt thereof.

	N HN O F	1
	1-1-N-1	
N NH NH NH	NH S	
N NH		
I		
CN NH OFFICE	c²n — h-	HN-NH

or a pharmaceutically acceptable salt thereof.

or a pharmaceutically acceptable salt thereof.

43. The compound according to Claim 1, wherein said compound is

	Ph NH NH N	Ph CI N N
Ph O O N N N N N N N N N N N N N N N N N		
		O H N H N


or a pharmaceutically acceptable salt thereof.

44. The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

	HIN-N-F
	□ HN N H

□ SHN-N=	0-3-0-h
I N N N N N N N N N N N N N N N N N N N	



or a pharmaceutically acceptable salt thereof.

46. The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

or a pharmaceutically acceptable salt thereof.

- 48. A pharmaceutical composition comprising an inert carrier and an 5 effective amount of a compound according to claim 1.
 - 49. The pharmaceutical composition according to claim 48 useful for the treatment of pain.
- 50. The pharmaceutical composition according to claim 48 useful for the treatment of migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.
- 51. A method of treating pain comprising a step of administering to
 15 one in need of such treatment an effective amount of a compound according to claim
 1.
- 52. A method of treating migraine, depression, anxiety, schizophrenia,
 Parkinson's disease, or stroke comprising a step of administering to one in need of
 such treatment an effective amount of a compound according to claim 1.